T1	Intervention 511 565	enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364).
T2	Intervention 586 841	randomly assigned in a 2:1 ratio to receive afatinib or chemotherapy (pemetrexed-cisplatin [LUX-Lung 3] or gemcitabine-cisplatin [LUX-Lung 6]), stratified by EGFR mutation (exon 19 deletion [del19], Leu858Arg, or other) and ethnic origin (LUX-Lung 3 only)
